Established Biomobie Corp in USA

Established Biomobie (Shanghai) Regenerative Medicine Co., Ltd. in Shanghai

Shanghai Fudan University and Jiao Tong University jointly conducted animal experiments on the treatment of myocardial ischemia and lower limb ischemia using Bioboosti®

Shanghai Jiao Tong University Xinhua Hospital Leads Successful Double-Blind Clinical Trial of Bioboosti® for Hypertension Treatment Obtained Class II medical device registration and market access approval by the China Shanghai FDA

Established Health Centers in Shanghai and Beijing

The Clinical Trial of Bioboosti for Insomnia Treatment was Conducted by Harvard University Strategic Cooperation Agreement with Ping An

Real-World Clinical Conclusions: Symptoms Improvement in 30,000 Cases of Chronic Disease Patients

Beijing Tiantan Hospital Completed a Clinical Trial of Bioboosti for Cerebral Glioma Edema Treatment. Attained FDA Class I Medical Device Registration in the United States

Conducting Clinical Trials on Myocardial Ischemia with Mayo Clinic Initiated Double-Blind Clinical Trials on Insomnia with West China Hospital，Sichuan University and Air Force Medical University

Conclusion of the Bioboosti® pilot clinical trial at Fuwai Hospital, focusing on coronary heart disease and myocardial ischemia. A Multi-center Clinical Trial on Myocardial Ischemia Had Been Initiated, Under the Leadership of Professor Ge Junbo from Zhongshan Hospital

Collaborated with China's leading healthcare platform, Yunque Medical. We expanded our product coverage to over 830 health centers, clinics, and community hospitals nationwide.

Initiated Clinical Trials for Pulmonary Arterial Hypertension Treatment with Beijing Fuwai Hospital